Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group

Marco Cicardi, Konrad Bork, Teresa Caballero, Timothy Craig, H. H. Li, Hilary Longhurst, Avner Reshef, Bruce Zuraw, Werner Aberer, Emel Aygören-Pürsün, Aleena Banerji, Janne Bjorkander, Isabelle Boccon-Gibod, Laurence Bouillet, France Grenoble, Maria Bova, Tom Bowen, Canada Calgary, Ferreira Manuel Branco, Anette BygumTeresa Caballero, Mauro Cancian, Maria Graça Castel-Branco, Caterina de Carolis, Enikö Mihály, Josè Fabiani, H. Farkas, Mark Gompels, Richard Gower, Adriane Groffik, Anete Grumach, Mar Guillarte, Erik Hack, Landeros Maria Hernandez, Allen Kaplan, Alicia Lara, Iris Leibovich, Henry Li, Bob Lock, William Lumry, Alejandro Malbran, Inmaculada Martinez-Saguer, Campos Matta, Marcus Maurer, Dumitru Moldovan, Vincenzo Montinaro, Sandra Nieto, Patrik Nordenfelt, Krystyna Obtulovicz, Roberto Perricone, Nieves Prior, Marc Riedl, Valle Rodrigues do, Chiara Savoca, Peter Spaeth, Petra Staubach-Renz, Marcin Stobiecki, Massimo Triggiani, Romualdo Vacchini, L. Varga, Andrea Zanichelli, Kian Zarchi, Sacha Zeerleder, Lorenza Zingale

Research output: Contribution to journalArticle

273 Citations (Scopus)

Abstract

A ngioedema owing to hereditary deficiency of C1 inhibitor (HAE) is a rare, life-threatening, disabling disease. In the last 2 years, the results of well-designed and controlled trials with existing and new therapies for this condition have been published, and new treatments reached the market. Current guidelines for the treatment for HAE were released before the new trials and before the new treatments became available and were essentially based on observational studies and expert opinion. To provide evidence-based HAE treatment guidelines supported by the new studies, a conference was held in Gargnano del Garda, Italy, from September 26 to 29, 2010. The meeting hosted 58 experienced HAE expert physicians, representatives of pharmaceutical companies and representatives of HAE patients' associations. Here, we report the topics discussed during the meeting and evidence-based consensus about management approaches for HAE in adult/adolescent patients.

Original languageEnglish
Pages (from-to)147-157
Number of pages11
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume67
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Hereditary Angioedemas
Angioedema
Guidelines
Patient Advocacy
Therapeutics
Expert Testimony
Italy
Observational Studies
Physicians
Pharmaceutical Preparations

Keywords

  • bradykinin receptor antagonist
  • C1 inhibitor
  • consensus document
  • hereditary angioedema
  • kallikrein inhibitor

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency : Consensus report of an International Working Group. / Cicardi, Marco; Bork, Konrad; Caballero, Teresa; Craig, Timothy; Li, H. H.; Longhurst, Hilary; Reshef, Avner; Zuraw, Bruce; Aberer, Werner; Aygören-Pürsün, Emel; Banerji, Aleena; Bjorkander, Janne; Boccon-Gibod, Isabelle; Bouillet, Laurence; Grenoble, France; Bova, Maria; Bowen, Tom; Calgary, Canada; Branco, Ferreira Manuel; Bygum, Anette; Caballero, Teresa; Cancian, Mauro; Castel-Branco, Maria Graça; de Carolis, Caterina; Mihály, Enikö; Fabiani, Josè; Farkas, H.; Gompels, Mark; Gower, Richard; Groffik, Adriane; Grumach, Anete; Guillarte, Mar; Hack, Erik; Hernandez, Landeros Maria; Kaplan, Allen; Lara, Alicia; Leibovich, Iris; Li, Henry; Lock, Bob; Lumry, William; Malbran, Alejandro; Martinez-Saguer, Inmaculada; Matta, Campos; Maurer, Marcus; Moldovan, Dumitru; Montinaro, Vincenzo; Nieto, Sandra; Nordenfelt, Patrik; Obtulovicz, Krystyna; Perricone, Roberto; Prior, Nieves; Riedl, Marc; Rodrigues do, Valle; Savoca, Chiara; Spaeth, Peter; Staubach-Renz, Petra; Stobiecki, Marcin; Triggiani, Massimo; Vacchini, Romualdo; Varga, L.; Zanichelli, Andrea; Zarchi, Kian; Zeerleder, Sacha; Zingale, Lorenza.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 67, No. 2, 02.2012, p. 147-157.

Research output: Contribution to journalArticle

Cicardi, M, Bork, K, Caballero, T, Craig, T, Li, HH, Longhurst, H, Reshef, A, Zuraw, B, Aberer, W, Aygören-Pürsün, E, Banerji, A, Bjorkander, J, Boccon-Gibod, I, Bouillet, L, Grenoble, F, Bova, M, Bowen, T, Calgary, C, Branco, FM, Bygum, A, Caballero, T, Cancian, M, Castel-Branco, MG, de Carolis, C, Mihály, E, Fabiani, J, Farkas, H, Gompels, M, Gower, R, Groffik, A, Grumach, A, Guillarte, M, Hack, E, Hernandez, LM, Kaplan, A, Lara, A, Leibovich, I, Li, H, Lock, B, Lumry, W, Malbran, A, Martinez-Saguer, I, Matta, C, Maurer, M, Moldovan, D, Montinaro, V, Nieto, S, Nordenfelt, P, Obtulovicz, K, Perricone, R, Prior, N, Riedl, M, Rodrigues do, V, Savoca, C, Spaeth, P, Staubach-Renz, P, Stobiecki, M, Triggiani, M, Vacchini, R, Varga, L, Zanichelli, A, Zarchi, K, Zeerleder, S & Zingale, L 2012, 'Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group', Allergy: European Journal of Allergy and Clinical Immunology, vol. 67, no. 2, pp. 147-157. https://doi.org/10.1111/j.1398-9995.2011.02751.x
Cicardi, Marco ; Bork, Konrad ; Caballero, Teresa ; Craig, Timothy ; Li, H. H. ; Longhurst, Hilary ; Reshef, Avner ; Zuraw, Bruce ; Aberer, Werner ; Aygören-Pürsün, Emel ; Banerji, Aleena ; Bjorkander, Janne ; Boccon-Gibod, Isabelle ; Bouillet, Laurence ; Grenoble, France ; Bova, Maria ; Bowen, Tom ; Calgary, Canada ; Branco, Ferreira Manuel ; Bygum, Anette ; Caballero, Teresa ; Cancian, Mauro ; Castel-Branco, Maria Graça ; de Carolis, Caterina ; Mihály, Enikö ; Fabiani, Josè ; Farkas, H. ; Gompels, Mark ; Gower, Richard ; Groffik, Adriane ; Grumach, Anete ; Guillarte, Mar ; Hack, Erik ; Hernandez, Landeros Maria ; Kaplan, Allen ; Lara, Alicia ; Leibovich, Iris ; Li, Henry ; Lock, Bob ; Lumry, William ; Malbran, Alejandro ; Martinez-Saguer, Inmaculada ; Matta, Campos ; Maurer, Marcus ; Moldovan, Dumitru ; Montinaro, Vincenzo ; Nieto, Sandra ; Nordenfelt, Patrik ; Obtulovicz, Krystyna ; Perricone, Roberto ; Prior, Nieves ; Riedl, Marc ; Rodrigues do, Valle ; Savoca, Chiara ; Spaeth, Peter ; Staubach-Renz, Petra ; Stobiecki, Marcin ; Triggiani, Massimo ; Vacchini, Romualdo ; Varga, L. ; Zanichelli, Andrea ; Zarchi, Kian ; Zeerleder, Sacha ; Zingale, Lorenza. / Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency : Consensus report of an International Working Group. In: Allergy: European Journal of Allergy and Clinical Immunology. 2012 ; Vol. 67, No. 2. pp. 147-157.
@article{e8e245ea211a45b3a3345e028a15fe56,
title = "Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group",
abstract = "A ngioedema owing to hereditary deficiency of C1 inhibitor (HAE) is a rare, life-threatening, disabling disease. In the last 2 years, the results of well-designed and controlled trials with existing and new therapies for this condition have been published, and new treatments reached the market. Current guidelines for the treatment for HAE were released before the new trials and before the new treatments became available and were essentially based on observational studies and expert opinion. To provide evidence-based HAE treatment guidelines supported by the new studies, a conference was held in Gargnano del Garda, Italy, from September 26 to 29, 2010. The meeting hosted 58 experienced HAE expert physicians, representatives of pharmaceutical companies and representatives of HAE patients' associations. Here, we report the topics discussed during the meeting and evidence-based consensus about management approaches for HAE in adult/adolescent patients.",
keywords = "bradykinin receptor antagonist, C1 inhibitor, consensus document, hereditary angioedema, kallikrein inhibitor",
author = "Marco Cicardi and Konrad Bork and Teresa Caballero and Timothy Craig and Li, {H. H.} and Hilary Longhurst and Avner Reshef and Bruce Zuraw and Werner Aberer and Emel Ayg{\"o}ren-P{\"u}rs{\"u}n and Aleena Banerji and Janne Bjorkander and Isabelle Boccon-Gibod and Laurence Bouillet and France Grenoble and Maria Bova and Tom Bowen and Canada Calgary and Branco, {Ferreira Manuel} and Anette Bygum and Teresa Caballero and Mauro Cancian and Castel-Branco, {Maria Gra{\cc}a} and {de Carolis}, Caterina and Enik{\"o} Mih{\'a}ly and Jos{\`e} Fabiani and H. Farkas and Mark Gompels and Richard Gower and Adriane Groffik and Anete Grumach and Mar Guillarte and Erik Hack and Hernandez, {Landeros Maria} and Allen Kaplan and Alicia Lara and Iris Leibovich and Henry Li and Bob Lock and William Lumry and Alejandro Malbran and Inmaculada Martinez-Saguer and Campos Matta and Marcus Maurer and Dumitru Moldovan and Vincenzo Montinaro and Sandra Nieto and Patrik Nordenfelt and Krystyna Obtulovicz and Roberto Perricone and Nieves Prior and Marc Riedl and {Rodrigues do}, Valle and Chiara Savoca and Peter Spaeth and Petra Staubach-Renz and Marcin Stobiecki and Massimo Triggiani and Romualdo Vacchini and L. Varga and Andrea Zanichelli and Kian Zarchi and Sacha Zeerleder and Lorenza Zingale",
year = "2012",
month = "2",
doi = "10.1111/j.1398-9995.2011.02751.x",
language = "English",
volume = "67",
pages = "147--157",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency

T2 - Consensus report of an International Working Group

AU - Cicardi, Marco

AU - Bork, Konrad

AU - Caballero, Teresa

AU - Craig, Timothy

AU - Li, H. H.

AU - Longhurst, Hilary

AU - Reshef, Avner

AU - Zuraw, Bruce

AU - Aberer, Werner

AU - Aygören-Pürsün, Emel

AU - Banerji, Aleena

AU - Bjorkander, Janne

AU - Boccon-Gibod, Isabelle

AU - Bouillet, Laurence

AU - Grenoble, France

AU - Bova, Maria

AU - Bowen, Tom

AU - Calgary, Canada

AU - Branco, Ferreira Manuel

AU - Bygum, Anette

AU - Caballero, Teresa

AU - Cancian, Mauro

AU - Castel-Branco, Maria Graça

AU - de Carolis, Caterina

AU - Mihály, Enikö

AU - Fabiani, Josè

AU - Farkas, H.

AU - Gompels, Mark

AU - Gower, Richard

AU - Groffik, Adriane

AU - Grumach, Anete

AU - Guillarte, Mar

AU - Hack, Erik

AU - Hernandez, Landeros Maria

AU - Kaplan, Allen

AU - Lara, Alicia

AU - Leibovich, Iris

AU - Li, Henry

AU - Lock, Bob

AU - Lumry, William

AU - Malbran, Alejandro

AU - Martinez-Saguer, Inmaculada

AU - Matta, Campos

AU - Maurer, Marcus

AU - Moldovan, Dumitru

AU - Montinaro, Vincenzo

AU - Nieto, Sandra

AU - Nordenfelt, Patrik

AU - Obtulovicz, Krystyna

AU - Perricone, Roberto

AU - Prior, Nieves

AU - Riedl, Marc

AU - Rodrigues do, Valle

AU - Savoca, Chiara

AU - Spaeth, Peter

AU - Staubach-Renz, Petra

AU - Stobiecki, Marcin

AU - Triggiani, Massimo

AU - Vacchini, Romualdo

AU - Varga, L.

AU - Zanichelli, Andrea

AU - Zarchi, Kian

AU - Zeerleder, Sacha

AU - Zingale, Lorenza

PY - 2012/2

Y1 - 2012/2

N2 - A ngioedema owing to hereditary deficiency of C1 inhibitor (HAE) is a rare, life-threatening, disabling disease. In the last 2 years, the results of well-designed and controlled trials with existing and new therapies for this condition have been published, and new treatments reached the market. Current guidelines for the treatment for HAE were released before the new trials and before the new treatments became available and were essentially based on observational studies and expert opinion. To provide evidence-based HAE treatment guidelines supported by the new studies, a conference was held in Gargnano del Garda, Italy, from September 26 to 29, 2010. The meeting hosted 58 experienced HAE expert physicians, representatives of pharmaceutical companies and representatives of HAE patients' associations. Here, we report the topics discussed during the meeting and evidence-based consensus about management approaches for HAE in adult/adolescent patients.

AB - A ngioedema owing to hereditary deficiency of C1 inhibitor (HAE) is a rare, life-threatening, disabling disease. In the last 2 years, the results of well-designed and controlled trials with existing and new therapies for this condition have been published, and new treatments reached the market. Current guidelines for the treatment for HAE were released before the new trials and before the new treatments became available and were essentially based on observational studies and expert opinion. To provide evidence-based HAE treatment guidelines supported by the new studies, a conference was held in Gargnano del Garda, Italy, from September 26 to 29, 2010. The meeting hosted 58 experienced HAE expert physicians, representatives of pharmaceutical companies and representatives of HAE patients' associations. Here, we report the topics discussed during the meeting and evidence-based consensus about management approaches for HAE in adult/adolescent patients.

KW - bradykinin receptor antagonist

KW - C1 inhibitor

KW - consensus document

KW - hereditary angioedema

KW - kallikrein inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84855779242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855779242&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.2011.02751.x

DO - 10.1111/j.1398-9995.2011.02751.x

M3 - Article

C2 - 22126399

AN - SCOPUS:84855779242

VL - 67

SP - 147

EP - 157

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 2

ER -